Guangdong Hec Technology Holding Co Ltd
SSE:600673
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.18
9.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guangdong Hec Technology Holding Co Ltd
Net Income (Common)
Guangdong Hec Technology Holding Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Guangdong Hec Technology Holding Co Ltd
SSE:600673
|
Net Income (Common)
¥239.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
5%
|
|
|
C
|
China Hongqiao Group Ltd
HKEX:1378
|
Net Income (Common)
¥18.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Shandong Nanshan Aluminium Co Ltd
SSE:600219
|
Net Income (Common)
¥4.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Aluminum Corporation of China Ltd
SSE:601600
|
Net Income (Common)
¥10.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
257%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Aluminium Co Ltd
SZSE:000807
|
Net Income (Common)
¥5.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Tianshan Aluminum Group Co Ltd
SZSE:002532
|
Net Income (Common)
¥3.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
39%
|
CAGR 10-Years
44%
|
|
Guangdong Hec Technology Holding Co Ltd
Glance View
Nestled in the vibrant economic landscape of China, Guangdong Hec Technology Holding Co Ltd operates with the intricacies of a well-oiled machine in the health sector. The company, with its focal point in pharmaceuticals, has been a significant player in the development, manufacturing, and sale of a variety of medicinal products. Its portfolio spans across anti-infectives, digestive medications, and cardiovascular treatments, amassing a reputation for innovation and quality. The company’s commitment to research and development is palpable, as it consistently invests in state-of-the-art laboratories and collaborations with leading scientific minds. This approach not only fuels its pipeline of groundbreaking therapies but also ensures a steady stream of products ready for market. The company's revenue engine hums efficiently through a strategic blend of domestic and international market penetration. By leveraging an extensive distribution network, Guangdong Hec Technology ensures its products reach both regional pharmacies and global pharmaceutical markets. Through meticulous marketing strategies and strategic partnerships, the company has adeptly navigated the complex waters of regulatory compliance and competitive pricing landscapes. Its financial fortitude is further bolstered by a judicious mix of pharmaceutical exports and local sales, highlighting its dual focus on global expansion and domestic consolidation. In this dance of science and commerce, Guangdong Hec Technology continues to solidify its stature, harnessing both innovation and keen business acumen to thrive in the ever-evolving pharmaceutical industry.
See Also
What is Guangdong Hec Technology Holding Co Ltd's Net Income (Common)?
Net Income (Common)
239.7m
CNY
Based on the financial report for Sep 30, 2024, Guangdong Hec Technology Holding Co Ltd's Net Income (Common) amounts to 239.7m CNY.
What is Guangdong Hec Technology Holding Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
Over the last year, the Net Income (Common) growth was -22%. The average annual Net Income (Common) growth rates for Guangdong Hec Technology Holding Co Ltd have been -24% over the past three years , -26% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
